Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations

The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute myeloid leukemia (AML) without FLT3-ITD, biallelic CEBPA-, or NPM1 mutations (here referred to as NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML) in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2017-11, Vol.28 (11), p.2793-2798
Hauptverfasser:	Heidrich, K, Thiede, C, Schäfer-Eckart, K, Schmitz, N, Aulitzky, W E, Krämer, A, Rösler, W, Hänel, M, Einsele, H, Baldus, C D, Trappe, R U, Stölzel, F, Middeke, J M, Röllig, C, Taube, F, Kramer, M, Serve, H, Berdel, W E, Ehninger, G, Bornhäuser, M, Schetelig, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Biomarkers, Tumor - genetics CCAAT-Enhancer-Binding Proteins - genetics Female fms-Like Tyrosine Kinase 3 - genetics Follow-Up Studies Hematopoietic Stem Cell Transplantation Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Leukemia, Myeloid, Acute - therapy Male Middle Aged Mutation Nuclear Proteins - genetics Nucleophosmin Prognosis Prospective Studies Remission Induction Survival Rate Transplantation, Homologous Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!